BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 73 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2013. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $7,312,000 | +64.9% | 1,155,104 | +14.9% | 7.86% | +80.4% |
| Q3 2016 | $4,433,000 | +55.3% | 1,005,104 | 0.0% | 4.36% | +47.4% |
| Q2 2016 | $2,854,000 | +79.2% | 1,005,104 | +78.5% | 2.96% | +113.9% |
| Q1 2016 | $1,593,000 | -71.4% | 562,943 | +50.6% | 1.38% | -12.1% |
| Q2 2015 | $5,579,000 | -64.6% | 373,686 | -78.6% | 1.57% | -56.6% |
| Q1 2015 | $15,752,000 | -25.7% | 1,744,356 | 0.0% | 3.63% | -37.8% |
| Q4 2014 | $21,211,000 | +24.3% | 1,744,356 | 0.0% | 5.84% | -23.9% |
| Q3 2014 | $17,060,000 | -23.3% | 1,744,356 | 0.0% | 7.67% | -35.5% |
| Q2 2014 | $22,241,000 | +20.5% | 1,744,356 | 0.0% | 11.89% | +23.9% |
| Q1 2014 | $18,455,000 | +38.4% | 1,744,356 | -0.6% | 9.59% | +33.7% |
| Q4 2013 | $13,333,000 | -16.0% | 1,754,356 | -19.5% | 7.18% | -18.2% |
| Q3 2013 | $15,875,000 | +910.5% | 2,180,656 | +115.2% | 8.77% | +651.2% |
| Q2 2013 | $1,571,000 | – | 1,013,442 | – | 1.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |